Literature DB >> 15727422

Pediatric supratentorial high-grade gliomas.

Mandeep S Tamber1, James T Rutka.   

Abstract

The purpose of this review is to highlight some of the pertinent concepts and controversies surrounding the diagnosis and treatment of pediatric supratentorial high-grade gliomas. Unlike the adult counterparts, pediatric high-grade gliomas are likely derived from distinct cytogenetic and molecular alterations. Surgery has been shown to play a role in extending patient survival. Some success is associated with the provision of chemotherapy. Radiotherapy remains an important adjunct in children older than age 3 years. The challenges involved in improving the poor prognosis of children in whom these very aggressive tumors have been diagnosed will be discussed, as well as some of the novel approaches being investigated to improve patient survival and quality of life.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15727422     DOI: 10.3171/foc.2003.14.2.2

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  21 in total

1.  Pediatric supratentorial high-grade glioma: multicenter retrospective observational study of the Korean Society for Pediatric Neuro-Oncology.

Authors:  Tae-Young Jung; Ji Yeoun Lee; Dong-Seok Kim; Hyeon Jin Park; Chae-Yong Kim; Young-Shin Ra; Mee-Jeong Lee; Seong-Ho Kim; Hee-Jo Baek; Il Han Kim; Kyung Duk Park; Seung-Ki Kim
Journal:  J Neurooncol       Date:  2014-11-04       Impact factor: 4.130

Review 2.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

Review 3.  Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies.

Authors:  Mandeep S Tamber; Krishan Bansal; Muh-Lii Liang; Todd G Mainprize; Bodour Salhia; Paul Northcott; Michael Taylor; James T Rutka
Journal:  Childs Nerv Syst       Date:  2006-09-02       Impact factor: 1.475

4.  Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.

Authors:  Hilko Ardon; Stefaan Van Gool; Isabel Spencer Lopes; Wim Maes; Raf Sciot; Guido Wilms; Philippe Demaerel; Patricia Bijttebier; Laurence Claes; Jan Goffin; Frank Van Calenbergh; Steven De Vleeschouwer
Journal:  J Neurooncol       Date:  2010-02-10       Impact factor: 4.130

5.  Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma.

Authors:  Christopher S Hong; Juan C Vasquez; Adam J Kundishora; Aladine A Elsamadicy; Jason M Beckta; Amrita Sule; Asher M Marks; Nalin Leelatian; Anita Huttner; Ranjit S Bindra; Michael L DiLuna; Kristopher T Kahle; E Zeynep Erson-Omay
Journal:  NPJ Genom Med       Date:  2020-06-01       Impact factor: 8.617

6.  LAPTM4B-35 is a novel prognostic factor for glioblastoma.

Authors:  Xiaoshud Dong; Kaoru Tamura; Daisuke Kobayashi; Noboru Ando; Kazutaka Sumita; Taketoshi Maehara
Journal:  J Neurooncol       Date:  2017-01-18       Impact factor: 4.130

Review 7.  Glioblastoma multiforme with very rapid growth and long-term survival in children: report of two cases and review of the literature.

Authors:  Mahmoud Reza Khalatbari; Mehrdokht Hamidi; Yashar Moharamzad
Journal:  Childs Nerv Syst       Date:  2011-06-08       Impact factor: 1.475

Review 8.  Pediatric high-grade glioma: current molecular landscape and therapeutic approaches.

Authors:  Steve Braunstein; David Raleigh; Ranjit Bindra; Sabine Mueller; Daphne Haas-Kogan
Journal:  J Neurooncol       Date:  2017-03-29       Impact factor: 4.130

Review 9.  Initial management of childhood brain tumors: neurosurgical considerations.

Authors:  Farideh Nejat; Mostafa El Khashab; James T Rutka
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

10.  Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells.

Authors:  Steven De Vleeschouwer; Isabel Spencer Lopes; Jan L Ceuppens; Stefaan W Van Gool
Journal:  J Neurooncol       Date:  2007-03-15       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.